Back to Search
Start Over
Safe and prolonged survival with Long-term exposure to Pomalidomide in Relapsed/Refractory Myeloma
- Source :
- Annals of Oncology, Annals of Oncology, Elsevier, 2016, 27 (5), pp.902-907. ⟨10.1093/annonc/mdw017⟩, Annals of Oncology, Oxford University Press (OUP), 2016, 27 (5), pp.902-907. ⟨10.1093/annonc/mdw017⟩, Annals of Oncology, 2016, 27 (5), pp.902-907. ⟨10.1093/annonc/mdw017⟩
- Publication Year :
- 2016
- Publisher :
- HAL CCSD, 2016.
-
Abstract
- International audience; Background - The IFM2009-02 trial studied pomalidomide (4 mg daily, 21/28 versus 28/28) and dexamethasone in very advanced relapsed or refractory multiple myeloma (RRMM). We observed that 40% of patients had a prolonged progression-free survival (PFS) and subsequently overall survival (OS). We sought to analyze the characteristics of these patients and study the effect of long exposure to pomalidomide. Design - We separated the studied population into two groups: 3 months to 1 year (
- Subjects :
- Male
0301 basic medicine
[SDV]Life Sciences [q-bio]
Gastroenterology
Dexamethasone
Bortezomib
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Multiple myeloma
Aged, 80 and over
education.field_of_study
Long-term treatment
Hematology
Middle Aged
Thalidomide
3. Good health
Oncology
030220 oncology & carcinogenesis
Female
Multiple Myeloma
medicine.drug
Adult
medicine.medical_specialty
Drug-Related Side Effects and Adverse Reactions
Population
[SDV.CAN]Life Sciences [q-bio]/Cancer
Continuous therapy
[SDV.BC]Life Sciences [q-bio]/Cellular Biology
Disease-Free Survival
03 medical and health sciences
Internal medicine
medicine
Humans
education
Aged
business.industry
medicine.disease
Pomalidomide
Confidence interval
Surgery
Regimen
030104 developmental biology
Drug Resistance, Neoplasm
Neoplasm Recurrence, Local
business
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Subjects
Details
- Language :
- English
- ISSN :
- 09237534 and 15698041
- Database :
- OpenAIRE
- Journal :
- Annals of Oncology, Annals of Oncology, Elsevier, 2016, 27 (5), pp.902-907. ⟨10.1093/annonc/mdw017⟩, Annals of Oncology, Oxford University Press (OUP), 2016, 27 (5), pp.902-907. ⟨10.1093/annonc/mdw017⟩, Annals of Oncology, 2016, 27 (5), pp.902-907. ⟨10.1093/annonc/mdw017⟩
- Accession number :
- edsair.doi.dedup.....103306da23b03737efae536ad967d487